Evaluation of the BD Phoenix CPO Detect Panel for Detection and Classification of Carbapenemase Producing .

Carbapenem-resistant (CRE) pose a serious public health threat due to their resistance to most antibiotics. Rapid and correct detection of carbapenemase producing organisms (CPOs) can help inform clinician decision making on antibiotic therapy. The BD Phoenix™ CPO detect panel, as part of antimicrobial susceptibility testing (AST), detects carbapenemase activity (P/N) and categorizes CPOs according to Ambler classes. We evaluated a CPO detect panel against 109 carbapenemase producing (CPE) clinical isolates from Korea. The panel correctly detected carbapenemases production in 98.2% ( = 107/109) isolates and identified 78.8% ( = 26/33) class A, 65.9% ( = 29/44) class B, and 56.3% ( = 18/32) class D carbapenemase producers as harboring their corresponding Ambler classes. Specifically, the panel correctly classified 81.3% ( = 13/16) of KPC isolates to class A. However, the panel failed to classify 40.0% ( = 4/10) IMP and 63.6% ( = 7/11) VIM isolates to class B. Despite 27.5% ( = 30/109) CPE not being assigned Ambler classes, all of them tested carbapenemase positive. Our results demonstrate that the CPO detect panel is a sensitive test for detecting CPE and classifying KPC as class A, helping with antibiotics selection, but one-third of CPE remained unclassified for Ambler classes.